WINSTON-SALEM, N.C. and RESEARCH TRIANGLE PARK, N.C. - June 26, 2001 - Pilot Therapeutics, Inc., a leading developer of natural therapeutics to treat chronic diseases, and Quintiles Transnational Corp. (Nasdaq: QTRN) today announced an alliance to commercialize Pilot's lead product, the first clinically validated natural therapy for people with asthma.

Under the agreement, Quintiles' commercialization unit, Innovex, would be able to become the exclusive sales services provider for Pilot's natural therapy for asthma, PLT 3514. Innovex's services would include hiring, training and deploying a sales force to promote the product to physicians for a five-year period. In addition, the agreement would enable Quintiles to be Pilot's preferred provider of pre-launch services and future clinical development services.

"The alliance between Pilot Therapeutics and Quintiles Transnational brings together two companies that are pioneers in their respective industries," said Floyd H. Chilton, Ph.D., founder, Chief Executive Officer and Chief Scientific Officer of Pilot. "Pilot is establishing a new model for the natural products industry by discovering and developing natural products in conjunction with two world-class medical centers - Johns Hopkins and Wake Forest University.

"PLT 3514, the first natural therapy for asthma, is supported by Phase I and II clinical trial data and will be promoted directly to physicians. Pilot's alliance with Quintiles provides us access to the outstanding commercial capabilities of Innovex, creating a synergy that we believe will dramatically change the natural products industry."

The alliance agreement also calls for PharmaBio Development, Quintiles' corporate ventures group, to provide Pilot a milestone-based, convertible line of credit to support its near-term development and pre-marketing needs. Based upon the results of the pre-launch sales forecast and approval by a joint marketing committee of Quintiles and Pilot representatives, PharmaBio Development also would share the expense of the Innovex sales force for PLT 3514 in return for royalties on sales for a seven-year period following launch.

Richard Johnson, M.D., Chief Executive Officer of Quintiles Commercialization North America, said: "Our commercialization alliance with Pilot is breaking new ground in the promotion of natural therapies to physicians, which I believe has tremendous potential. We look forward to applying our full commercialization expertise to meet market demands for clinically validated natural therapies."

Asthma afflicts more than 17 million people in the United States and accounts for 10 million physician office visits annually. Pilot expects to launch PLT 3514 as a natural medicine early next year.

About Pilot Therapeutics, Inc. and PLT 3514
Pilot Therapeutics, Inc. is a venture-backed biopharmaceutical company formed in 1998 based on pioneering Functional Liponomics(TM) platform research. This research identified several key areas where the dysfunctional regulation of bioactive lipids was a significant cause of human disease and revealed natural and pharmaceutical therapeutic strategies for treating those diseases.

Pilot Therapeutics' mission is to lead the market in serving those who suffer from chronic human diseases, including asthma, hay fever, coronary heart disease, cystic acne and cancer, by providing consumers with clinically proven natural and pharmaceutical products that have been demonstrated to be safe and effective utilizing the most stringent scientific standards. For more information about Pilot Therapeutics, visit the company's Web site at www.pilotp.com.

Pilot's lead product, PLT 3514, is the first natural therapy for asthmatics supported by Phase I and II human safety and efficacy data to block the production of leukotrienes, a class of inflammatory lipid molecules that are involved in the pathogenesis of inflammatory disorders such as asthma. The formulation of PLT 3514 combines gammalinolenic acid (GLA), a fatty acid with anti-inflammatory activity found in high concentrates in glycerolipids of certain plants, and a delta-5 desaturase inhibitor.

About Quintiles Transnational, Innovex and PharmaBio Development
Quintiles Transnational is the world's leading provider of information, technology and services to bring new medicines to patients faster and improve healthcare. Headquartered near Research Triangle Park, North Carolina, Quintiles employs a global workforce of 18,000 in 39 countries. Quintiles Transnational is a member of the S&P 500 and Fortune 1000. For more information visit the company's web site at www.quintiles.com.

Innovex, the commercialization unit of Quintiles Transnational, is the world's leading commercial solutions provider. Innovex offers sales and marketing services designed to accelerate the success of pharmaceutical and biotech products. Over the past five years Innovex has created 72 contract sales forces - comprising more than 10,000 sales representatives total - to detail products in more than 30 therapeutic categories, including 19 new-product launches.

PharmaBio Development, the corporate ventures group of Quintiles Transnational, creates innovative partnering solutions to help life-science companies develop and market new products to improve human health.

Information in this press release contains "forward-looking statements" regarding Quintiles that involve risks and uncertainties that could cause actual results to differ materially, including without limitation, the risk that the market for our products and services will not grow as we expect, the risk that PharmaBio transactions will not generate revenues or profit at the rate or levels we anticipate, our ability to efficiently distribute backlog among therapeutic business units and match demand to resources, actual operating performance, the ability to maintain large client contracts or to enter into new contracts, changes in trends in the pharmaceutical industry, and the ability to operate successfully in new lines of business. Additional factors that could cause actual results to differ materially are discussed in the company's recent filings with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, its Form 8-Ks, and its other periodic reports, including Form 10-Qs. Statements in this release regarding Pilot Therapeutics and Quintiles have been made by their respective company under that company's sole responsibility.